Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25327553 | 0.88 | IMPDH2 (0.36) | PTGS2ALOX5IMPDH2AKR1B1 | |
| SCHEMBL28116022 | 0.87 | ALOX5 (0.33) | PTGS2ALOX5CA2CA4TDP1 | |
| SCHEMBL25328660 | 0.86 | ALOX5 (0.34) | PTGS2ALOX5IMPDH2AKR1B1 | |
| SCHEMBL2956027 | 0.86 | PTGS2 (0.42) | PTGS2CA2CA4CA1CA6 | |
| SCHEMBL5588494 | 0.85 | TDP1 (0.36) | PTGS2ALOX5CA2CA4TDP1 | |
| SCHEMBL5587793 | 0.85 | ALOX5 (0.33) | PTGS2ALOX5CA2CA4TDP1 | |
| SCHEMBL25328865 | 0.82 | ALOX5 (0.37) | PTGS2ALOX5CA2CA4TDP1 | |
| SCHEMBL25329338 | 0.81 | IMPDH2 (0.44) | ALOX5IMPDH2 | |
| SCHEMBL1760474 | 0.80 | GABRA1 (0.38) | — | |
| SCHEMBL25328823 | 0.77 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583813-B2 | Polymerization inhibitors | BASF SE (DE) | 2026-03-24 | — | — | US | disclosed |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| CN-115697954-A | Polymerization inhibitor | 巴斯夫欧洲公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | RCE1, CABLES1, DPYD | PTGS2 594/4885ALOX5 1518/4885CA2 2500/4885 |
| US-12583813-B2 | Polymerization inhibitors | PTGS1, PTGER1, POT1 | PTGS2 8/4885ALOX5 560/4885CA2 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.